Nkarta Inc (NKTX)

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage...

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer Canada NewsWire NEW YORK, May 29, 2026...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Canada NewsWire SAN FRANCISCO, May...

Form 8-K - Current report

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material